Skip to content
Nonprofiteer
← All organizations

INTREPID ALLIANCE INC

EIN 35-2711268 CAMBRIDGE, MA

Revenue 2024
$2,245,192
Expenses 2024
$1,930,908

As filed

Subsection
06
NTEE code
H03
Classification
2000
Street
1 BROADWAY STE 14

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Other organizations at this address

17 other organizations in the IRS Business Master File list the same street address. matched by us

This address is a suite or unit (STE 14). Organizations that share one are often clients of the same office-services firm, accountant or registered agent rather than related to each other.

We match the street line and ZIP code as the IRS gives them, ignoring case and outer spaces and nothing else, so "AVE" and "AVENUE" count as different streets and this list can miss some. A shared address can mean related organizations or a shared office, but it can also be a registered agent, a mail drop or a service provider holding mail for unrelated clients. It is not, by itself, evidence that two organizations are connected.

Mission and programs · 2024

Mission

THE PRIMARY PURPOSE OF THE CORPORATION IS TO PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH PANDEMIC PREPAREDNESS EFFORTS. THE CORPORATION WILL PURSUE THIS PURPOSE BY PROMOTING THE DEVELOPMENT OF NEW TREATMENTS FOR EMERGING VIRAL PANDEMIC PATHOGENS THROUGH COORDINATED EARLY SCIENCE, POLICY AND ADVOCACY, STAKEHOLDER ENGAGEMENT THAT FACILITATES INFORMATION SHARING, AND ADVANCING AND CREATING EFFICIENCIES IN EARLY RESEARCH AND DEVELOPMENT AMONG ITS MEMBERS AND OTHERS IN THE ANTIVIRAL R&D ECOSYSTEM. IN THIS WAY THE CORPORATION AIMS TO SUPPORT THE 100 DAY MISSION, AN INTERNATIONAL EFFORT BY THE INTERNATIONAL PANDEMIC PREPAREDNESS SECRETARIAT (IPPS.ORG) "TO PREPARE AS MUCH AS POSSIBLE SO THAT WITHIN THE FIRST 100 DAYS A PANDEMIC THREAT IS IDENTIFIED AN INITIAL REGIMEN OF THERAPEUTICS" CAN BE MADE AVAILABLE BY RESEARCH ENTERPRISES THAT ARE SAFE, EFFECTIVE AND AFFORDABLE.

Activities or mission (Part I)

PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH ANTIVIRAL PANDEMIC PREPAREDNESS EFFORTS.

  • BEYOND COVID-19, GLOBALIZATION, URBAN EXPANSION, AND EXPLOITATION OF NATURAL HABITATS SUGGEST HUMANITY WILL FACE NEW FORMS OF RESPIRATORY AND OTHER PATHOGENS THAT HOLD THE POTENTIAL TO CAUSE PANDEMICS. ORALLY AVAILABLE SMALL-MOLECULE ANTIVIRAL DRUGS FOR RAPID MOBILIZATION AND DISTRIBUTION ARE A CRITICAL TOOL TO PROTECT SOCIETIES FROM ANOTHER VIRAL PANDEMIC. UNLIKE SOME VACCINES AND ANTIBODIES, ANTIVIRAL THERAPIES MIGHT BE LESS PRONE TO THE IMPACT OF VIRUS GENETIC EVOLUTION, MAY BE EFFECTIVE AGAINST A BROAD RANGE OF VIRUSES, AND CAN CHANGE THE COURSE OF DISEASE EVEN AFTER INFECTION. MOST SMALL MOLECULE ANTIVIRALS CAN BE PRODUCED RAPIDLY AND COST-EFFECTIVELY AT A GLOBAL SCALE IN EXISTING FACILITIES, BUT THEY REQUIRE YEARS TO DISCOVER AND DEVELOP, SO IT IS CRITICAL TO PROMOTE AND SUPPORT RESEARCH, ADVOCACY, AND SCIENTIFIC INFORMATION SHARING ACROSS THE ACADEMIC BIOTECH AND PHARMACEUTICAL INDUSTRY. IN ORDER TO CREATE EFFICIENCIES IN THE R&D ECOSYSTEM, THE CORPORATION WILL COLLABORATE WITH PARTNERS IN OTHER SECTORS AND ITS MEMBERS IN EXPLORING REDUNDANCIES AND OPPORTUNITIES TO COLLABORATE FOR THE BENEFIT OF HUMANITY SUCH AS SHARING NEW RESEARCH FINDINGS, CREATING GUIDELINES SUCH AS TARGET PRODUCT PROFILES, BENCHMARKING GLOBAL R&D EFFORTS AGAINST PATHOGENS OF PANDEMIC CONCERN AND CREATING A LISTING OF PROMISING LEAD PRODUCT CANDIDATES BY RESEARCHERS GLOBALLY. WE HOPE TO ACCELERATE THE COLLECTIVE UNDERSTANDING OF VIRAL TARGETS AND INCREASE THE LIKELIHOOD OF THE R&D ECOSYSTEM IN IDENTIFYING PROMISING LEADS. THE CORPORATION INTENDS TO FACILITATE FURTHER SCIENTIFIC INFORMATION SHARING BY DEVELOPING WHITE PAPERS ON RELEVANT TOPICS, PERFORMING A LANDSCAPE AND NEEDS ASSESSMENT ACROSS PUBLIC AND PRIVATE ANTIVIRAL RESEARCH SECTORS, AND PROVIDING KNOWLEDGE-SHARING OPPORTUNITIES THROUGH ORGANIZING MEETINGS AND SEMINARS. THE CORPORATION ALSO ORGANIZED AND PRODUCED A GLOBAL SUMMIT ON ANTIVIRAL PREPAREDNESS FOR 100 STAKEHOLDERS, PUBLISHED AND DISSEMINATED THE ANTIVIRAL SUMMIT PROCEEDINGS AND RECOMMENDATIONS, RESEARCHED, ANALYZED AND AUTHORED THE ANTIVIRAL CLINICAL DEVELOPMENT LANDSCAPE FOR PUBLICATION IN JANUARY 2024 AND DEVELOPED A TARGET COMPOUND PROFILE TO GUIDE ACADEMIC, BIOTECH, PHARMA AND GOVERNMENT DRUG DEVELOPERS IN THEIR R&D FOR ANTIVIRALS.

As filed on the 2024 return.

Officers and directors · 2024

As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

  • James Anderson

    PRESIDENT

    Total calculated
    $0
    Hours/week
    1

  • Lydia Ogden

    SECRETARY

    Total calculated
    $0
    Hours/week
    1

  • Derek Wallace

    DIRECTOR (AS OF 11/2024)

    Total calculated
    $0
    Hours/week
    1

  • Kenneth Bradley

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • Kumar Singh Saikatendu

    DIRECTOR (THRU 08/2024)

    Total calculated
    $0
    Hours/week
    1

  • Margaret Chu-Moyer

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • Michelle Parks

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • Sujata Vaidyanathan

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • Tomas Cihlar

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • James Bergin

    TREASURER

    Total calculated
    $0
    Hours/week
    1

  • Nina Hill

    SECRETARIAT

    Total calculated
    $298,844
    From this org
    $298,844
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $298,844
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $298,844

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

  • 2024
    Revenue
    $2,245,192
    Expenses
    $1,930,908
    Contributions
    $0
    Grants paid
    $0
  • 2023
    Revenue
    $1,500,000
    Expenses
    $1,303,244
    Contributions
    $0
    Grants paid
    $0
  • 2022
    Revenue
    $1,499,980
    Expenses
    $236,250
    Contributions
    $0
    Grants paid
    $0

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

  • 2021 · 990

    Revenue
    $500,000
    Expenses
    $47,600
    Assets (EOY)
    $500,000

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all.

Grants made

No itemized grants to organizations. Schedule I is filed only by organizations that granted more than $5,000 to a recipient, so most filers have none.

Grants received

No itemized grant names this organization as a recipient. Only grants over $5,000 are itemized, and only by filers of the full Form 990.

Other IRS files

Auto-Revocation List

Not listed. The IRS publishes this list for organizations whose exemption was automatically revoked for failing to file for three consecutive years.

Publication 78

Not present in the most recent drop.

These are two separate IRS files on two separate schedules, shown as published and not reconciled with each other. Neither is a statement about whether a contribution is deductible today: 19,245 organizations appear in Publication 78 while the IRS's own revocation file lists them as currently revoked, more than half of those revoked before 2019. Absence from Publication 78 is evidence of nothing, and presence is not evidence either. Verify current status with the IRS before relying on it.

What this page reflects

The registration facts above come from the IRS Business Master File published 13 October 2026 and read 1 November 2026, for every organization at once. Returns through tax year 2024, the newest we have parsed for this organization.